Evidence map›Paper›PMID 34302260›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2021

Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149.

Marc Vanhove, Bernard Noppen, Jean-Marc Wagner, Tine Van Bergen, Philippe Barbeaux, Alan W Stitt

Open access · hybridAbstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Editorial: Kinin 2022 Meeting, Annecy, France.Journal of clinical medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marc VanhoveOxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium. marc.vanhove@oxurion.com.ORCID 0000-0003-4144-7688
Bernard NoppenOxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium.
Jean-Marc WagnerHaute École de la Province de Liège, Avenue Montesquieu 6, 4101, Seraing, Belgium.
Tine Van BergenOxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium.
Philippe BarbeauxOxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium.
Alan W StittOxurion N.V., Gaston Geenslaan 1, 3001, Leuven, Belgium.
Oxurion (Belgium) · BEHaute École de la Province de Liège · BEQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravitreal (IVT) injection of pharmacological agents is an established and widely used procedure for the treatment of many posterior segment of the eye diseases. IVT injections permit drugs to reach high concentrations in the retina whilst limiting systemic exposure. Beyond the risk of secondary complications such as intraocular infection, the potential of systemic adverse events cannot be neglected. Therefore, a detailed understanding of the rules governing systemic exposure following IVT drug administration remains a prerequisite for the evaluation and development of new pharmacological agents intended for eye delivery. We present here a novel mathematical model to describe and predict circulating drug levels following IVT in the rabbit eye, a species which is widely used for drug delivery, pharmacokinetic, and pharmacodynamic studies. The mathematical expression was derived from a pharmacokinetic model that assumes the existence of a compartment between the vitreous humor compartment itself and the systemic compartment. We show that the model accurately describes circulating levels of THR-149, a plasma kallikrein inhibitor in development for the treatment of diabetic macular edema. We hypothesize that the model based on the rabbit eye has broader relevance to the human eye and can be used to analyze systemic exposure of a variety of drugs delivered in the eye.

Indexed as

Diabetic RetinopathyMacular EdemaAnimalsPharmaceutical PreparationsRabbitsRetinaVitreous BodyPharmaceutical PreparationsIntegrated pharmacokineticsIntravitreal administrationSystemic exposure

Identifiers

PMID34302260
PMCPMC8604835
OpenAlexW3187020174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.